Enterprise Value

-41.86M

Cash

100.7M

Avg Qtr Burn

-13.12M

Short % of Float

10.94%

Insider Ownership

0.53%

Institutional Own.

44.30%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ME-344 (Mitochondrial Inhibitor) Details
Cancer, Solid tumor/s, Colorectal cancer

Phase 1b

Data readout

Voruciclib (CDK Inhibitor) Details
B-cell malignancies, Acute myeloid leukemia, Cancer

Phase 1b

Data readout

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued